Novartis delivers 250,000,000th Coartem® treatment and becomes first
healthcare company to join Unit
Novartis delivers 250,000,000th Coartem® treatment and becomes first healthcare company to join United Against Malaria partnership
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ * Physician and Novartis Chairman and CEO Daniel Vasella delivers 250,000,000th treatment to healthcare clinic in Dar es Salaam, Tanzania * Novartis becomes first healthcare company to join United Against Malaria, a pan-Africa campaign to end malaria-related deaths and suffering * With an estimated 630,000 lives saved, Novartis nonprofit Malaria Initiative is the largest access-to-medicines program for the developing world[1]Basel, July 6, 2009 - Today Novartis announced the delivery of the250,000,000th treatment of Coartem, a highly-effectiveartemisinin-based combination therapy (ACT) for the treatment ofmalaria, with cure rates of more than 95%[2]*. To mark this occasion,Dr. Daniel Vasella, Chairman and CEO of Novartis, delivered themilestone dose to Mwananyamala District Hospital in Dar es Salaam,Tanzania.Reinforcing Novartis' long-term commitment to patients in thedeveloping world, Dr. Vasella also announced that Novartis is thefirst healthcare company to join United Against Malaria (UAM), aconsortium that strives to raise awareness of malaria and achieve theshared goal of ending malaria deaths in Africa by 2015.Preventable and curable, malaria remains a devastating diseaseinfecting more than 250 million people each year and causing anestimated 880,000 deaths[3]. Its toll is heaviest among youngchildren in sub-Saharan Africa, where it is estimated that a childdies of malaria every 30 seconds[3]."With 250 million treatments provided and an estimated 630,000 livessaved, the Novartis Malaria Initiative is the industry's largestaccess-to-medicines program in the developing world[1]," said Dr.Vasella. "However, malaria demands a collaborative approach. JoiningUnited Against Malaria in its campaign is a promising way to relieveunnecessary suffering due to malaria."Novartis is the first healthcare company to join UAM, whose foundingpartners include Comic Relief, Johns Hopkins University, Malaria NoMore, the ONE Campaign, PATH, Population Services International, RollBack Malaria and the United Nations Foundation and the Bill & MelindaGates Foundation. Aiming to raise awareness and renew worldwidecommitment to ending malaria, UAM will stage several high-profilepublic events in late 2009 and 2010 leading up to next year's WorldCup in South Africa."Novartis is a major player in the global effort to end malariadeaths in Africa by 2015," said Scott Case, CEO of Malaria No Moreand a United Against Malaria partner. "We congratulate Novartis onthis remarkable achievement and welcome Novartis to the UnitedAgainst Malaria team. This invaluable partnership shows how teamworkis vital in the race to save lives."Coartem is a highly-effective three-day malaria treatment with curerates of more than 95%, even in areas of multi-drug resistance[2]. Itis approved for use in over 80 countries worldwide. In January 2009,Novartis and Medicines for Malaria Venture introduced Coartem®Dispersible, a new child-friendly formulation. Sweet-tasting andeasily dispersed in water, Coartem® Dispersible eases administrationand enables accurate dosing for children, the most vulnerable groupof malaria patients.DisclaimerThe foregoing release contains forward-looking statements that can beidentified by terminology such as "estimated," "promising,""commitment," "preventable and curable," "aiming to," "will," orsimilar expressions, or by express or implied discussions regardingpotential contributions by Novartis to the fight against Malaria orto other causes, or regarding potential future revenues from Coartem®or Coartem® Dispersible. You should not place undue reliance on thesestatements. Such forward-looking statements reflect the currentviews of management regarding future events, and involve known andunknown risks, uncertainties and other factors that may cause actualresults to be materially different from any future results,performance or achievements expressed or implied by such statements.There can be no guarantee that Novartis will maintain itscontributions to the fight against Malaria or to other causes atpresent levels in the future. Nor can there be any guarantee thatCoartem® or Coartem® Dispersible will achieve any particular levelsof revenue in the future. In particular, management's expectationsregarding Coartem® or Coartem® Dispersible could be affected by,among other things, unexpected regulatory actions or delays orgovernment regulation generally; unexpected clinical trial results,including unexpected new clinical data and unexpected additionalanalysis of existing clinical data; the company's ability to obtainor maintain patent or other proprietary intellectual propertyprotection; competition in general; government, industry and generalpublic pricing pressures; the impact that the foregoing factors couldhave on the values attributed to the Novartis Group's assets andliabilities as recorded in the Group's consolidated balance sheet,and other risks and factors referred to in Novartis AG's current Form20-F on file with the US Securities and Exchange Commission. Shouldone or more of these risks or uncertainties materialize, or shouldunderlying assumptions prove incorrect, actual results may varymaterially from those anticipated, believed, estimated or expected.Novartis is providing the information in this press release as ofthis date and does not undertake any obligation to update anyforward-looking statements contained in this press release as aresult of new information, future events or otherwise.About NovartisNovartis AG provides healthcare solutions that address the evolvingneeds of patients and societies. Focused solely on healthcare,Novartis offers a diversified portfolio to best meet these needs:innovative medicines, preventive vaccines, diagnostic tools,cost-saving generic pharmaceuticals, and consumer health products.Novartis is the only company with leading positions in these areas.In 2008, the Group's continuing operations achieved net sales of USD41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2billion was invested in R&D activities throughout the Group.Headquartered in Basel, Switzerland, Novartis Group companies employapproximately 96,700 full-time-equivalent associates and operate inmore than 140 countries around the world. For more information,please visit http://www.novartis.com.Novartis was named a Super Sector Leader by the Dow JonesSustainability Index (DJSI) in 2008. In the same year, 74 millionpatients around the world benefited from Novartis programs valued atUSD 1.26 billion. These initiatives range from drug donation andresearch programs to combat neglected diseases like malaria,tuberculosis and leprosy in developing nations, to patient assistanceprograms that help cancer patients receive the most innovative andeffective treatments available. For further information on ourcorporate citizenship activities, please consult:http://www.corporatecitizenship.novartis.com.About United Against MalariaUAM is a coalition of organizations including founding partners ComicRelief, Johns Hopkins University, Malaria No More, the ONE Campaign,PATH, Population Services International, Roll Back Malaria and theUnited Nations Foundation. UAM is supported by the Bill & MelindaGates Foundation. It is a partnership of football stars,non-governmental organizations, foundations, governments,corporations, and the general public who have joined forces ahead ofthe 2010 World Cup in South Africa to unite in the fight againstmalaria. By partnering with footballers, UAM aims to raise globalawareness and renew worldwide commitment to ending malaria, as wellas to increase the use of prevention tools and malaria treatment inAfrica. UAM will stage several high-profile public events in late2009 and 2010, leading up to the 2010 World Cup in South Africa, formore information please go to www.unitedagainstmalaria.org.References[1] The International Federation of Pharmaceutical Manufacturers andAssociations. Available at: www.ifpma.org.[2] Abdulla S. et al. Efficacy and safety of arthemeter-lumefantrinedispersible tablets compared with crushed commercial tablets inAfrican infants and children with uncomplicated malaria: arandomised, single blind, multicentre trial. Lancet . Publishedonline.[3] Malaria Fact Sheet. World Health Organization Web site. Availableat: http://www.who.int/mediacentre/factsheets/fs094/en/.* Cure rates are PCR-corrected in the mITT population. For fulldetails see reference. # # #Novartis Media RelationsEric Althoff Peter ShelbyNovartis Global Media Relations Novartis Pharma Communications+41 61 324 7999 (direct) +41 61 324 4470 (direct)+41 79 593 4202 (mobile) +41 79 597 6353 (mobile)eric.althoff(at)novartis.com peter.shelby(at)novartis.comCentral media line: +41 61 324 2200E-mail: media.relations(at)novartis.comhttp://hugin.info/134323/R/1327203/312602.pdf --- End of Message ---Novartis International AGPosfach Basel WKN: 904278; ISIN: CH0012005267; Index: SLCI, SMI, SPI, SLIFE;Listed: Main Market in SIX Swiss Exchange, ZLS in BX Berne eXchange;
Bereitgestellt von Benutzer: hugin
" alt="Komplett reports revenue of MNOK 319 in June 2009.>">Datum: 06.07.2009 - 07:15 Uhr
Sprache: Deutsch
News-ID 3244
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 279 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis delivers 250,000,000th Coartem® treatment and becomes first
healthcare company to join Unit"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
